Slides
Page 1
PeptiDream Revolutionizing Drug Discovery FY 2026 1H Financial Results Presentation August 12 , 2026 Copyright @ 2026 PeptiDream Inc. All Rights Reserved PeptiDream Inc. ( TSE : 4587 )
Page 2
2 FY2026 Q2 Financial Results AGENDA Patrick C Reid CEO Masato Murakami EVP: Radiopharma Business President: PDRadiopharma Catherine Ohura EVP: Operations Jun Kono EVP: Strategy Kodo Shikata EVP: People & Culture Today’s Speakers Q&A CLOSING REMARKS FINANCIAL UPDATE INTRODUCTIONS of NEW EVPs PDRadiopharma UPDATE BUSINESS UPDATE & HIGHLIGHTS SUSTAINABILITY
Page 3
3 FY2026 Q2 Financial Results The Evolution of PeptiDream Focus on Three Strategic Priorities to Drive our Transformation Expansion/Advancement of Clinical-Stage Pipeline Robust Pipeline Diversified Across 5 Core Focus Areas Disciplined P&L and Cash Flow Management • Increasing overall number of programs in clinical pipeline; main driver of future revenue & corporate value. • Clinical development of wholly-owned programs to compliment collaboration partnered clinical programs. • Advancing a broad range of preclinical and clinical programs across five therapeutic areas where macrocyclic peptides offer significant advantages. • Asset creation engine to support further clinical pipeline expansion as well as new partnering / out-licensing opportunities. • A focus on revenue from R&D funding and milestones from existing deals, upfront payments from new partnerships, as well as PDRadiopharma growth. • Maintain strict cost controls; balancing R&D investment versus annual profitability & cash flow generation. Global Discovery & Development Company Global Biopharma CompanyGlobal Discovery CompanyUniversity Startup Company 20262006 2016
Page 4
4 FY2026 Q2 Financial Results Clinical Pipeline Expansion — Driving Value Creation Focus on Expanding RI and Non-RI Clinical Pipeline to Drive Future Revenue Growth Revenue driven by New Deals (UF) & Milestones Revenue driven by Royalties & Product Sales Current Future 2023 # of Clinical Programs 2024 2025 2026E 2030s 5 7 13 19 -25 Deals (UF) & Milestones Japan Radiopharm Business Royalties from Collaboration Partner Product Sales (RI & non - RI) PeptiDream Product Sales ◆ Disciplined Cost Control ◆ Invest Profits into Further Pipeline Expansion Clinical Programs Key Drivers of Future Revenue
Page 5
5 FY2026 Q2 Financial Results Our 5 Core Focus Areas — A Wealth of Opportunities Creating a stable and diversified revenue base from multiple business opportunities Note: 1) PSMA Theranostics are partnered with Curium Pharma, 2) 64Cu-ATSM is partnered with LinqMed 5 Core Areas of FocusRadiopharma “RI” Business Peptide “non-RI” Business ✓ Rapidly growing clinical pipeline! • Currently 13 programs in clinical development spanning phases. • Japan; PSMA1), ATSM2) • Partnered; GPC3, FAP , HER2, etc. • In-House; CA9 ✓ Robust preclinical pipeline, both In-House & Partnered. • Top pharma partners in field • In-House; CLDN18.2, CDH3, etc. • Asset creation engine ✓ Strong foundation and PET market growth in Japan Radiopharma business. ✓ Multiple business opportunities exist across our RI efforts • New partnerships/in-licensing (Japan) • New partnerships/out-licensing (ex-Japan) ✓ Steady progress across a wide range of programs including oral! • Currently 6 programs in clinical development – all partnered programs. • Exciting partnered preclinical programs moving toward clinical stage. • Internal asset creation – IL17, myostatin, etc., provide option flexibility ✓ Robust preclinical pipeline of partnered Oligo-PDC programs progressing toward clinical development. • Roster of top pharma partners in field • Advancing toward clinical entry • High interest in new partnering ✓ Major partnership progressing well. • Advancing toward clinical entry • High interest in new partnering ✓ Multiple business opportunities exist across our MPC efforts • Internal asset creation • High interest in new partnering Peptide-Cytotoxin Conjugates Cytotoxic[-PDC] 4 Multi-Functional Peptide Conjugates MPC 5 Oral/Peptide Therapeutics PepTx 2 Peptide-Oligo Conjugates Oligo[-PDC] 3 Radiopharmaceuticals RI[-PDC] 1
Page 6
6 FY2026 Q2 Financial Results Our Five Core Focus Areas – Asset Creation Engine Leverages the unique strengths of macrocyclic peptides across both internal and partnered efforts Multi-Functional Peptide Conjugates (MPC) Peptide-Oligo Conjugates Peptide-RI Conjugates1 Oral/ injectable Peptide Therapeutics 3 Peptide-Cytotoxin Conjugates4 5 ✓ Ideal modality for targeted RI delivery ✓ High target selectivity ✓ Excellent tumor penetration and retention ✓ Rapid clearance ✓ Versatile and scalable platform ✓ One of hottest fields with 2 recent approvals validating the modality ✓ Oral dosing with efficacy of injectable biologic ✓ High systemic exposure with exceptional target selectivity and potency ✓ Favorable safety profile ✓ Ideal delivery vehicles ✓ Allow for precise tissue targeting ✓ Enhanced cellular delivery ✓ Improved efficacy & safety ✓ Applicable across diverse targets & indications ✓ Ideal for tumor targeted delivery ✓ Builds on RI delivery concept & advantages ✓ Higher tumor-to-normal tissue exposure ✓ Access targets ADCs cannot ✓ Simple/scalable manufacturing ✓ Extends payload (RI, Oligo, Cytotoxin) delivery concept to recruiting/engaging ✓ Immune engagers – efficacy of biologics with potential safety advantages ✓ Powerful potential of bi- and tri-specific molecules with simplicity of peptides 2
Page 7
7 FY2026 Q2 Financial Results FY2026 1H Highlights — 6 Programs Entered Clinical Pipeline FY2026 Guidance for New Clinical Entries Already Achieved 1 2 3 4 2023 2024 2025 2026 5 7 13 19 - 25 Peptide (non-RI) RI Program/ modality Indication Partner Started AK1940 Autoimmune disease Asahi Kasei Therapeutics Apr. 2026 [177Lu]Lu-DWJ1551) Various cancers Novartis June 2026 [68Ga]Ga-DWJ1551) PD-32766T RCC In-House July 2026 PD-32766D Not Disclosed (PET imaging) Not disclosed (immune function) MSD2) August 2026 Note: 1) Novartis is the sponsor of the study 2) Merck & Co., Inc., Rahway, NJ, USA # of clinical programs at the end of year Currently 19 Programs in Clinical Development This trend is expected to continue beyond 2027 6 new clinical programs in 1H- 2026
Page 8
8 FY2026 Q2 Financial Results Disease Area Pipeline P0 P1 P2 P3 (Japan) (Overseas) Malignant Brain Tumors 64Cu-ATSM LinqMed SM2)-RI Ph3 Ongoing － Prostate Cancer 177Lu-PSMA I&T 64Cu-PSMA I&T Curium Pharma SM-RI Registrational Trial Initiated Ph3 Completed3) Ph3 Ongoing Hepatocellular Carcinoma 225Ac-GPC3 (RYZ801) 68Ga-GPC3 (RYZ811) RayzeBio P4)-RI Global Study Prep. Ph1/1b Ongoing PDAC/NSCLC/ BC/CRC 177Lu-FAP (FXX489/NNS309) 68Ga-FAP (FXX489/NNS309) Novartis P-RI － Ph1 Ongoing Renal Cell Carcinoma 225Ac-CA9 (PD-32766T) 64Cu-CA9 (PD-32766D) In-house P-RI Ph0 Completed Ph1 Ongoing (US) BC/ NSCLC/ GEJ/ bladder cancer [177Lu]Lu-DWJ155 [68Ga]Ga-DWJ155 Novartis P-RI Ph1 Ongoing Ph1 Ongoing Gastric cancer 225Ac-CLDN18.2 (PD-29875T) 64Cu-CLDN18.2 (PD-29875D) In-house P-RI IND-enabling/ Ph0 Ongoing － Head and Neck Cancer 225Ac/177Lu-CDH3 64Cu/68Ga-CDH3 In-house P-RI IND-enabling/ Ph0 Prep. － Oncology Not yet disclosed RayzeBio P-RI － Selected Clinical Dev. Candidate Oncology Various Undisclosed programs Various partners/ in-house P-RI Not Disclosed Not Disclosed Various Cancers 18F-PD-L1 (BMS-986229) Bristol Myers Squibb P-RI － Ph1 Completed Immune Function Not yet disclosed MSD5) P-RI Ph1 Ongoing Pipeline Overview: Radiopharmaceuticals IND-enabling / Ph0 Ph1 (Escalation/Expansion) Ph2/Ph3 (Registrational)Disease Area Program Theranostics / TherapeuticsDx1) 2026 Progress Updates from FY2025 Partner Development Stage Japan Overseas Note: Above list only includes major pipeline programs in IND or later stages. 1) Dx: Diagnostics, 2) SM: small molecule, 3) Enrollment completed and the primary endpoint has been met., 4) P: peptide, 5) Merck & Co., Inc., Rahway, NJ, USA
Page 9
9 FY2026 Q2 Financial Results Disease Area Pipeline P0 P1 P2 P3 (Japan) (Overseas) Allergic Diseases KIT Inhibitor (MOD-B) Alivexis SM IND-enabling － Obesity/ Muscle Disorders Oral Myostatin Inhibitor In-house Peptide Pre-clinical Obesity － Inflammatory / Immunology Oral IL-17A/F Inhibitor In-house Peptide Pre-clinical － Inflammatory Diseases Not yet disclosed Johnson & Johnson Peptide Pre-clinical － Not Disclosed Oral/ Peptide Therapeutics Various Partners/ in-house Peptide － － Not Disclosed Oligo-PDC Various Partners Oligo- PDC － － Not Disclosed Cytotoxic-PDC MSD1) Cytotoxic- PDC － － Not Disclosed MPCs (Immune Engagers, etc.) In-house MPC － － Disease Area Pipeline P0 P1 P2 P3 (Japan) (Overseas) Acromegaly GhR Antagonist (ALXN2420) AstraZeneca Peptide － Ph2 Ongoing Multiple Myeloma CD38-ARMTM (BHV-1100 + NK) Biohaven MPC － Ph1a/1b Completed COVID-19 S2-protein Inhibitor (PA-001) PeptiAID Peptide Clinical Research Completed Ph1 Completed Not Disclosed Merck (Not disclosed) MSD1) Peptide － Ph1 Ongoing Inflammatory Diseases Merck (Not disclosed) MSD1) Peptide － Ph1 Ongoing Autoimmune Diseases Selective TNFR1 inhibitor (AK1940) Asahi Kasei Therapeutics Peptide Ph1 Ongoing － Pipeline Overview: Peptide (non-RI) Note: Above list only includes major pipeline programs in IND or later stages. 1) Merck & Co., Inc., Rahway, NJ, USA Disease Area Program Clinical ProgramsSelected Preclinical Programs 2026 Progress Updates from FY2025 Partner Development Stage Japan Overseas Pre-clinical/ IND-enabling Ph1 Ph2 Ph3
Page 10
10 FY2026 Q2 Financial Results Major Clinical Pipeline Advances in FY2026 1H Clinical development progress across in-house and partnered programs Note: 1) Merck & Co., Inc., Rahway, NJ, USA, 2) Novartis is the sponsor of the study ✓TNFR1 inhibitor Asahi Kasei Therapeutics Entered Ph1 April 2026 ✓Collaboration Johnson & Johnson Identified Clinical Candidate January 2026 Ph0 ✓177Lu-PSMA-I&T Entered Registrational Trial Feb 2026 ✓64Cu-PSMA-I&T LPLD - Registrational Trial June 2026 Clinical Candidate Ph1 Registrational ✓64Cu-PD-29875 targeting CLDN18.2 Entered Ph0 June 2026 ✓[177Lu]Lu-DWJ155 targeting HER2 Novartis2) Entered Ph1 June 2026 ✓[68Ga]Ga-DWJ155 targeting HER2 Novartis2) Entered Ph1 June 2026 ✓225Ac‐PD-32766 targeting CA9 Entered Ph1 July 2026 ✓64Cu-PD-32766 targeting CA9 Entered Ph1 July 2026 ✓Collaboration MSD1) Entered Ph1 August 2026 Theranostic pairs
Page 11
11 FY2026 Q2 Financial Results PDRadiopharma: Commercial Strength into Future Product Value Commercial growth provides a durable foundation, while late-stage assets and policy support future revenue STRATEGIC ENABLER National policy recognition Development, manufacturing, supply & healthcare infrastructure Improving commercialization readiness COMMERCIAL ENGINE +30% YoY PET Product Revenue Growth Durable commercial foundation VALUE CATALYSTS 64Cu-PSMA I&T1) data readout: FY2026 H2 177Lu-PSMA I&T1) registrational study 64Cu-ATSM2) Ph3 registrational study PDRadiopharma combines a growing commercial base with late-stage assets and integrated capabilities that create a path to potential future product revenue in Japan. FY26 1H Radiopharma segment revenue: ¥8,025m (+¥242m YoY) Note: 1) PSMA Theranostics are partnered with Curium Pharma, 2) 64Cu-ATSM is partnered with LinqMed
Page 12
12 FY2026 Q2 Financial Results 2025 1H 2026 1H Commercial Engine: PET Revenue Grew 30% YoY Amyvid and FDG growth strengthen PDRadiopharma’s commercial revenue base Note: 1) Comparing FY2026 1H PET products revenue with FY2025 1H PET products revenue, 2) FDG: Fluorodeoxyglucose Key Growth Drivers • Amyvid Utilization expanding with the amyloid- treatment market • FDG Continued growth supported by flexible dosing • PET demand Broader utilization across diagnostic applications PET growth strengthens PDRadiopharma’s commercial foundation while supporting continued investment in late-stage programs. FDG2) Amyvid PET products revenue growth Radiopharmaceutical Business Revenue ¥8.0bn in FY2026 1H +3.1% YoY
Page 13
13 FY2026 Q2 Financial Results Advancing Late-Stage Assets to Potential Product Revenue in Japan Establishing an integrated diagnostic–therapeutic franchise in Japan Note: 1) PSMA Theranostics are partnered with Curium Pharma, 2) Dx: diagnostics 3) Tx: Therapeutics 4) Androgen receptor signaling inhibitor, 5) mCRPC: metastatic castration-resistant prostate cancer, 6) 64Cu-ATSM is partnered with LinqMed 64Cu-PSMA I&T1) (Dx2)) June 2026 Patient dosing completed FY2026 H2 Data readout expected FY2027 NDA planned Recurrence detection Metastatic disease assessment Patient selection for PSMA-targeted therapy 64Cu Therapeutic candidate for recurrent malignant glioma 64Cu-ATSM6) June 2024 First Patient Dosed P3 Registrational study underway FY2028 NDA planned First diagnostic-therapeutic integrated PSMA franchise in prostate cancer Second late-stage opportunity for future NEAR-TERM CATALYST February 2026 First patient dosed Registrational study underway FY2029 NDA planned 177Lu 177Lu-PSMA I&T1) (Tx3)) Treatment of patients with post- ARSI4), pre-taxane mCRPC5) PDRadiopharma is positioned to convert successful clinical assets into product revenue through its regulatory, manufacturing, supply and commercial capabilities in Japan. Potential future product revenue following successful development, regulatory approval and launch
Page 14
14 FY2026 Q2 Financial Results Radiopharmaceuticals Recognized in Japan’s National Policy Growth Strategy and Honebuto Policy 2026 strengthen policy focus on RI-based medicines Note: Growth Strategy Council is a government advisory body established under the Headquarters for Japan's Growth Strategy within the Cabinet. JAEC (Japan Atomic Energy Commission) is a Committee established in Cabinet Office. Policy developments • Honebuto Policy 2026 Radiopharmaceuticals included in Japan’s national policy agenda • Japan Atomic Energy Commission of Japan Cabinet Office Dedicated expert panel established in April 2026 RI-based medicines explicitly addressed • RI supply-chain resilience • Domestic manufacturing capabilities • Treatment capacity and hospital infrastructure • Coordination across the path to adoption Investing in New Manufacturing Capacity for Future Proprietary Radiopharmaceutical Launches amid an Increasingly Supportive Policy Environment JAPAN GROWTH STRATEGY 17 Strategic Sectors National priority RI-based medicines were highlighted as a priority area in Drug Discovery & Advanced Healthcare.（July 2026） No.11 Drug Discovery & Advanced Healthcare A national priority for Japan’s long-term competitiveness Explicit RI policy commitment Honebuto Policy 2026
Page 15
15 FY2026 Q2 Financial Results Overview of FY2026 1H Consolidated Results Note: Any fractional amount less than one million yen is disregarded. Consolidated Results (JPY M) FY2025 Q2 Results FY 2026 Q2 Results YoY FY2026 Forecasts Revenue 8,543 9,226 +683 32,000 Drug Discovery and Development Business 760 1,201 +441 Radiopharmaceutical Business 7,783 8,025 +242 EBITDA (1,609) (1,409) +200 Operating Profit (2,625) (2,534) +91 4,600 Profit attributable to owners of the Company (2,122) (1,999) +123 3,000 Comprehensive Income (2,122) (2,005) +116 Earnings Per Share (JPY) (16.40) (15.51) +0.89
Page 16
16 FY2026 Q2 Financial Results Reaffirmed FY 2026 Financial Guidance Progress remains on track and our FY2026 guidance remains unchanged High partnering interest, multiple discussions ongoing PET sales growing Late-stage trials on track FY2026 guidance remains unchanged Drug Discovery & Development Radiopharma FY2026 Forecast e.g.; Myostatin, IL17 15.0 1H 9.2 17.0 32.0 + α+ α Revenue not factored into guidance Company Guidance for FY2026 (¥bn) Revenue ¥32.0 bn Operating Income ¥4.6 bn *For each Major Internal Program we are focused on finding the right partner to both develop and maximize the value of each program. + α represents potential partnering/out-licensing deals that were not included in FY2026 guidance therefore representing potential upside.
Page 17
17 FY2026 Q2 Financial Results Strong Cash Position to Execute Strategy Investments in internal R&D programs, clinical development, and infrastructure/capability expansion • Expecting Cash position to strengthen further with new partnerships/deals in FY26 and FY27. • Increase in R&D expenditures largely related to CA9, CLDN18.2, & PSMA clinical development costs as well as IL17, Myostatin, and MPC related research costs in FY26. (¥6.5 FY26 estimate vs ¥5.0 FY25 actual) • Annual R&D budget/investment to be balanced versus annual revenue/profitability projections. Investment in development of wholly-owned assets Investment in continued business expansion • Both capital projects are expected to be funded through long- term bank loans at attractive rates • Efforts underway to apply for various government incentive programs, certain tax benefits, as well as subsidy programs to offset costs Cash on hand ¥23.6bn New Manufacturing Plant New Research Building Location： Tonomachi, Kanagawa Timeframe: 2027 - 2029 Investment： ¥ 12-15bn Location： Kazusa, Chiba Timeframe: 2027 - 2028 Investment： ¥ 10-12bn Note: Any fractional amount less than one hundred million yen is disregarded.
Page 18
18 FY2026 Q2 Financial Results New Leadership Team from July 1 Patrick Reid Representative Director & CEO Masato Murakami Board Director, EVP (Radiopharma Business & Development) Christian Cunningham EVP (Research) Catherine Ohura EVP (Operations) Jun Kono EVP (Strategy) Kodo Shikata EVP (People & Culture) Yen Ting Chen VP (Business Development & Alliance Management) Naoki Kawamura VP (Radiopharma Business) Taiki Kou VP (Strategy & Operations) Kengo Miyagawa VP (Finance) Chieko Inoue VP (Legal & Intellectual Property) Yuko Okimoto VP (Corporate Communications)
Page 19
19 FY2026 Q2 Financial Results Welcoming New EVPs Catherine Ohura, MS, PMP; Executive Vice President: Operations • Representative Director and General Manager for Illumina Japan, leading business growth in Japan for Illumina products and services (Next Generation Sequencers, etc.). • Representative Director and General Manager of Labcorp Laboratories Japan • Chief Executive Officer (CEO) of the Global Health Innovative Technology (GHIT) Fund, driving international public–private partnerships in global health. • Leadership experience from Bristol Myers Squibb (working in both, US headquarters and Japan affiliate), including leading large-scale global organizations both in R&D and Commercial organizations. • Also serves as an External Director of Sugi Holdings Co., Ltd. Jun Kono, MBA; Executive Vice President: Strategy • Japan Commercial Head at Astellas Pharma, leading commercial strategy and operations in one of the company’s key markets. • Senior leadership roles based in the US and Europe for globalization of pharma business and execution of regional operations, in addition to leading global business development to shape R&D portfolio. • Brings a combination of strong leadership track record of strategy, business development, commercial and global/regional operations in established global biopharma organization. • Jun Kono has received his Master of Business Administration degree with honor from the University of Chicago Booth School of Business. Kodo Shikata, PhD; Executive Vice President: People & Culture • Head of Global HR Strategy at Eisai, leading company-wide initiatives to strengthen organizational effectiveness and global talent capabilities. • Principal Scientist at Eisai Product Creation Systems in the Neurology Unit at its London research laboratory, following an early career in research. • Holds a Ph.D. in medicine from Okayama University Graduate School of Medicine.
Page 20
20 FY2026 Q2 Financial Results Sustainability as a Foundation for Next-Generation Medicines Strengthening the Foundation for Sustainable Value Creation through Sustainability and Business Growth Enhanced Corporate Governance with a New Leadership Structure Governance Climate Water People Para Athlete Tsukimura Captured Gold Medal at the 2025 Wheelchair Rugby Asia-Oceania Championship 80% of Group-wide Electricity Consumption Powered by Renewable Energy Set a 2030 Group-wide Water Reduction Target Note: FTSE Russell (the trading name of FTSE International Limited and Frank Russell Company) confirms that PeptiDream has be en independently assessed according to the index criteria and has satisfied the requirements to become a constituent of the FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index. Created by the global index provider FTSE Russell, these i ndices are designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices, and are used by a wide variety of market participants to create and assess responsible investment funds and other products. THE INCLUSION OF PEPTIDREAM INC. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF PEPTIDREAM INC. BY MSCI OR ANY OF ITS AFFILI ATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES. (Progress Since FY2025) Advancing Our Sustainability Initiatives External Recognition Driven by Our ESG Performance Evaluates environmental disclosure and carbon efficiency Gender Diversity Recognition 6 consecutive years 5 consecutive years CDP 2025 Climate “A List”
Page 21
21 Q&A
Page 22
22 Appendix
Page 23
23 FY2026 Q2 Financial Results PeptiDream – Mission, Vision, Values Striving towards fulfilling our Mission, achieving our Vision and delivering our Values Mission Vision Value As The Global Leading Peptide Drug Discovery Company Our mission is to discover the next generation of transformational medicines that will drastically improve the lives of patients worldwide. Our vision is to continue to uncover and expand on the power of macrocyclic peptides to unlock novel therapeutic and diagnostic possibilities through strong research and global collaboration. Our culture is anchored in the belief that every employee has the ability to be exceptional. We strive to create an environment where EXPERTISE is rewarded, PASSION is celebrated, and INTEGRETY is ingrained across every level of our organization.
Page 24
24 FY2026 Q2 Financial Results PeptiDream Overview PeptiDream and PDRadiopharma ◼ PeptiDream is a drug discovery company with a vertically integrated radiopharmaceutical subsidiary (PDRadiopharma) focused on the discovery, development, and commercialization of peptide-based therapeutics, peptide-drug conjugates, and radiopharmaceuticals (radiotherapeutics/radiodiagnostics) ◼ Combined company has 750+ employees, spanning discovery, development, manufacturing, regulatory, and sales in Japan ◼ PeptiDream (established in 2006) is largely credited with establishing the macrocyclic peptide field – high global reputation across the pharma industry. ◼ Collaborations with the majority of the world’s pharmaceutical companies ◼ PDRadiopharma (established in 1968) is one of two radiopharmaceutical companies licensed to operate in Japan (currently sells 8 radiotherapeutic and 21 radiodiagnostic products in Japan) ◼ Ideally positioned to capture a large share of the radiopharmaceutical field in Japan, while contributing through partnerships globally Largest Biotech Company in Japan The Global Leader in the Discovery of Peptide Therapeutics Leading Targeted-radiopharmaceutical Position in Japan PDRadiopharma Ibaraki Lab HQ Manufacturing and Research Sites Sales Offices (8) HQ & Research Laboratory New Research Building Kazusa Akademia Park New RI Manufacturing Plant PDRadiopharma Kawasaki Lab PeptiDream HQ PDRadiopharma Tokyo HQ TSE Prime: 4587 PDRadiopharma Chiba Manufacturing Site (Sanmu City)
Page 25
25 FY2026 Q2 Financial Results PeptiDream – The Epicenter of Peptide Drug Discovery (2006) Few big pharma engaged in peptide drug discovery Every big pharma engaged in peptide drug discovery (Today) PeptiDream has played a significant role in advancing Peptide Drug Discovery PeptiDream’s Evolving Proprietary PDPS® Drug Discovery Platform Amino Acid (AA) Building Blocks PeptiDream’s 3,000+ AAs Randomized DNA Library (e.g.) 10 positions with 20 building blocks 2010 = 10,240,000,000,000 different peptides in a library Trillions of Peptides in Each Library Robust, cell-free synthesis derived by nature’s way of making peptides Each peptide “barcoded” via its mRNA/cDNA tag High Rate of Hit Finding SuccessContinuously Evolving Platform Discover high affinity and highly selective macrocyclic peptide binders to almost any target quickly and efficiently Macrocyclic peptides Yields unique hit candidates unlike any other technology Technology can be used to optimize and fine-tune the drug-like properties Continuous expansion of AA building blocks that libraries be made with and optimized form (grew from 200 to >3,000) Automation of the platform (high throughput) Growing in-silico methods and computer simulation & modeling to predict optimal features Protected by a broad patent portfolio
Page 26
26 FY2026 Q2 Financial Results PDRadiopharma: Current Key Products Overview Note: FDG = Fluorodeoxyglucose; MCI: mild cognitive impairment; PD = Parkinson’s Disease; DLB = Dementia with Lewy Bodies; . As of July 2026. Sodium Iodide Capsule - 131I Hyperthyroidism/ Primary and Metastatic Thyroid Cancer Ultra-Techne Kow® SPECT 99mTc Thyroid Disease/ Brain Diseases/ Salivary Gland Disease Brain Bone Heart Thyroid Therapeutics Diagnostics Kidney/ Urinary Tract Neuroendocrine Cancer AMYViD® PET 18F Visualization of beta amyloid plaques in the brain of patients with MCI or suspected to have dementia due to Alzheimer’s Disease TAUVID® PET 18F Imaging Tau pathology in Alzheimer’s Disease Neurolite SPECT 99mTc Cerebral Blood Flow MyoMIBG® SPECT 123I Heart Disease/ Pheochromocytoma/ Neuroblastoma/ PD/ DLB Cardiolite® SPECT 99mTc Heart Disease/ Hyperparathyroidism TI201 SPECT 201TI Heart Disease Techne® MDP SPECT 99mTc Bone Scintigraphy FDG PET 18F Malignant Tumor/ Heart Disease/ Intractable Partial Epilepsy/ Large-vessel Vasculitis Raiatt MIBG - 131I MIBG avid Pheochromocytoma/ Paraganglioma/ Nueroblastoma OctreoScan SPECT 111In Somatostatin Receptor Scintigraphy Techne® DTPA SPECT 99mTc Renal Scintigraphy Current Key Marketed Products
Page 27
27 FY2026 Q2 Financial Results Total Solution Provider in Japan Radiopharmaceuticals Field Radiopharmaceuticals Products Diagnostics Injection System & Operational Support Software Solution Management System Therapeutics Injection System Portable Dosage Recorder Scheduling Assist • Easily digitalize dosage history and actual dosage • Nuclear medicine exam. scheduling INJECTOR/ DISPENSER • Automated injection • Automated device that collects from multiple and aliquots desired volume • Provides total of 22 radiodiagnostic products Image Analysis Solutions • AMYViD dedicated brain imaging analysis solution • Cerebral blood flow analysis solution • Myocardial blood flow and function analysis solution • Bone scintigraphy image analysis solution International Standards- Compliant Systems • Medical information system designed for electronic recording, managing and optimizing medical radiation dose • Provides total of 8 radiotherapeutic products
Page 28
28 FY2026 Q2 Financial Results Consolidated/Equity Method Applied Companies Note: Increase or decrease in the value of our shares is recorded as comprehensive income or loss, for PeptiStar, Alivexis and LinqMed. Consolidation Accounting Equity Method Accounting Parent company Subsidiary Affiliated Companies Radiopharma Business (2022-) COVID-19 Therapeutics (2020-) Drug Discovery and Development Business Segment Radiopharmaceutical Business Segment Discovery Collaboration1 2 3 Radiopharmaceutical Development, Manufacturing & Commercialization 4 Growth Factor Business (2020-)39.4% 39.5% 100% 1 2 Share of profit (loss) of investments accounted for using equity method recorded as non-operating income or loss PDPS® Technology Licensing Proprietary Programs for Outlicensing
Page 29
29 FY2026 Q2 Financial Results <20% 39.5% 39.4% <15% <5% Major Progress of PeptiDream’s Equity Holdings Note: (Year) represents the year that PeptiDream invested in the company, 1) former company name: modulus 100% Peptide CDMO Business (2017-) • Expanding the peptide and oligonucleotide API manufacturing business • Equity capital raise including participation from four new investors COVID-19 Therapeutics (2020-) • Completed Ph1 clinical trial (Sep. 2025) Growth Factor Business (2020-) • Launched PDGF-AA Alternative Peptide in July 2026 • Total of 14 marketed products Radiopharmaceutical Development, Manufacturing and Sales (2022-) • Registrational trials of 177Lu- PSMA (Tx) and 64Cu-PSMA (Dx) were initiated Computational Drug Discovery (2017-) • Partnering discussions in progress for KIT inhibitor program Strategic Partnership in Radiopharmaceuticals (2023-) • Co-development and commercialization of 64Cu-ATSM (malignant brain tumor) • Ph3 study from Jun. 2024 1)
Page 30
30 FY2026 Q2 Financial Results External Directors at PeptiDream Independent External Director (Auditing Committee Member) Junko Utsunomiya (Attorney) • Joined PeptiDream in Mar 2021, after working at Nagashima Ohno & Tsunematsu, Utsunomiya Shimizu & Haruki Management Legal Office as a founding partner • Currently Independent Outside Director (Auditing Committee Member) at PeptiDream Independent External Director (Auditing Committee Member) Yukinori Hanafusa (Certified Public Accountant) • Joined PeptiDream in Sep 2017, after working at Aoyama Audit Corporation, Accounting Works Co., Ltd. as Founding Representative Director, ARCLAND SERVICE HOLDINGS CO., LTD as Director • Currently Independent Outside Director (Auditing Committee Member) at PeptiDream Independent External Director (Auditing Committee Member) Kiichiro Kamiya • Joined PeptiDream in Mar 2025, after working at Hoechst Japan Ltd., Director and President of JSR Life Sciences Corporation, Director of MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., Senior Officer and Deputy General Manager of Life Sciences Division of JSR Corporation • Currently Independent Outside Director (Auditing Committee Member) at PeptiDream Independent External Director (Auditing Committee Member) Junko Nishiyama • Joined PeptiDream in Mar 2025, after working at Lion Corporation, where she held several key positions including Director, Packaging Engineering Research Laboratories, R&D Headquarters; Director, CSR Promotion Dept.; Audit & Supervisory Board Member, etc. • Outside Director (Member of the Audit Committee) of EBARA CORPORATION and Outside Audit & Supervisory Board Member of TODA CORPORATION (to present) • Currently Independent Outside Director (Auditing Committee Member) at PeptiDream
Page 31
31 FY2026 Q2 Financial Results Analyst Coverage Note: Created by PeptiDream (as of July 31, 2026) Company/ Organization Analyst Iwai Cosmo Securities Co., Ltd. Kazuyoshi Saito ACE Research Institute Inc. Tomohiko Ikeno SMBC Nikko Securities Inc. Hiroshi Wada SBI Securities Co., Ltd. Ryuta Kawamura Goldman Sachs Japan Co., Ltd. Akinori Ueda Jefferies (Japan) Limited Miyabi Yamakita Citigroup Global Markets Japan Inc. Hidemaru Yamaguchi Daiwa Securities Co. Ltd Kazuaki Hashiguchi Nomura Securities Co., Ltd. Hiroyuki Matsubara Marusan Securities Co., Ltd. Tsuyoshi Ohno Mizuho Securities Co., Ltd. Yuriko Ishida
Page 32
32 Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements are current plans, forecasts, assumptions and strategies based on currently available information. There are various inherent risks as well as uncertainties involved. The actual results of business performance may differ from those forecasts due to various factors. These factors include, but are not limited to: (1) risks of delays, interruptions or failures associated with drug discovery and development; (2) risks of unexpected program disruptions or terminations due to changes in client policies; (3) risks associated with manufacturing products and the procurement of raw materials; (4) the impact of reduced competitiveness due to the competitors and competing technologies; (5) declining product sales capabilities; (6) adverse rulings in infringements or significant litigation against our Group's intellectual property rights; (7) adverse changes in economic conditions and related laws and regulations; and (8) fluctuations in interest rates and currency exchange rates. The information in this material with respect to drugs (including those under development) is not intended to provide advertising or medical advice. This material is intended to provide information on our Group's business and is not intended to solicit investment in securities. PeptiDream assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.